A molecular study of pathways involved in the inhibition of cell proliferation in neuroblastoma B65 cells by the GSK-3 inhibitors lithium and SB-415286

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 9 B, 2009, Pages 3906-3917

  Pizarro, Javier G ^a   Folch, Jaume ^b   Esparza, José Luis ^c   Jordan, J ^d   Pallàs, Mercè ^a   Camins, Antoni ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^c FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

^d UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

Apoptosis; B65 cells; Cdc2; GSK3; Lithium; SB 415286

Indexed keywords

3 (3 CHLORO 4 HYDROXYPHENYLAMINO) 4 (4 NITROPHENYL) 1H PYRROLE 2,5 DIONE; 3-(3-CHLORO-4-HYDROXYPHENYLAMINO)-4-(4-NITROPHENYL)-1H-PYRROLE-2,5-DIONE; AMINOPHENOL DERIVATIVE; APOPTOSIS INDUCING FACTOR; CELL CYCLE PROTEIN; CELL DIVISION CYCLE 2 PROTEIN, RAT; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; LITHIUM; MALEIMIDE DERIVATIVE; SIRT2 PROTEIN, RAT; SIRTUIN 2;

ANIMAL; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL CYCLE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; NEUROBLASTOMA; RAT; TUMOR CELL LINE;

AMINOPHENOLS; ANIMALS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; LITHIUM; MALEIMIDES; NEUROBLASTOMA; RATS; SIRTUIN 2;

EID: 77649126352     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00389.x     Document Type: Article

References (54)

1. Forde JE, Dale TC. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci. 2007, 64:1930-44.
2. Phiel CJ, Klein PS. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol. 2001, 41:789-813.
3. Chuang DM, Manji HK. In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked. Biol Psychiatry. 2007, 62:4-6.
4. Gould TD, Picchini AM, Einat H. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets. 2006, 7:1399-409.
5. Meijer L, Flajolet M, Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci. 2004, 25:471-80.
6. Gould TD, Manji HK. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology. 2005, 30:1223-337.
7. Avila J, Hernández F. GSK-3 inhibitors for Alzheimer's disease. Expert Rev Neurother. 2007, 7:1527-33.
8. Wang W, Yang Y, Ying C. Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity. Neuropharmacology. 2007, 52:1678-84.
9. Ougolkov AV, Billadeau DD. Targeting GSK-3: a promising approach for cancer therapy. Future Oncol. 2006, 2:91-100.
10. Sun A, Shanmugam I, Song J. Lithium suppresses cell proliferation by interrupting E2F-DNA interaction and subsequently reducing S-phase gene expression in prostate cancer. Prostate. 2007, 67:976-88.
11. Takahashi-Yanaga F, Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal. 2008, 20:581-9.
12. Ryves WJ, Dajani R, Pearl L. Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochem Biophys Res Commun. 2002, 290:967-72.
13. Yeste-Velasco M, Folch J, Trullàs R. Glycogen synthase kinase-3 is involved in the regulation of the cell cycle in cerebellar granule cells. Neuropharmacology. 2007, 53:295-307.
14. García-Pérez J, Avila J, Díaz-Nido J. Lithium induces morphological differentiation of mouse neuroblastoma cells. J Neurosci Res. 1999, 57:261-70.
15. Karlovic D, Jakopec S, Dubravcic K. Lithium increases expression of p21(WAF/Cip1) and survivin in human glioblastoma cells. Cell Biol Toxicol. 2007, 23:83-90.
16. Mao CD, Hoang P, DiCorleto PE. Lithium inhibits cell cycle progression and induces stabilization of p53 in bovine aortic endothelial cells. J. Biol. Chem. 2001, 276:26180-8.
17. Facci L, Stevens DA, Skaper SD. Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity. Neuroreport. 2003, 14:1467-70.
18. Coghlan MP, Culbert AA, Cross DA. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol. 2007, 88:793-803.
19. Cao Q, Lu X, Feng YJ. Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res. 2006, 16:671-7.
20. Christensen BM, Kim YH, Kwon TH. Lithium treatment induces a marked proliferation of primarily principal cells in rat kidney inner medullary collecting duct. Am J Physiol Renal Physiol. 2006, 291:F39-48.
21. Erdal E, Ozturk N, Cagatay T. Lithium-mediated downregulation of PKB/Akt and cyclin E with growth inhibition in hepatocellular carcinoma cells. Int J Cancer. 2005, 115:903-10.
22. Mazor M, Kawano Y, Zhu H. Inhibition of glycogen synthase kinase-3 represses androgen receptor activity andprostate cancer cell growth. Oncogene. 2004, 23:7882-92.
23. Garcea G, Manson MM, Neal CP. Glycogen synthase kinase-3 beta; a new target in pancreatic cancer. Curr Cancer Drug Targets. 2007, 7:209-15.
24. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther. 2007, 6:1151-8.
25. Di Daniel E, Mudge AW, Maycox PR. Comparative analysis of the effects of four mood stabilizers in SH-SY5Y cells and in primary neurons. Bipolar Disord. 2005, 7:33-41.
26. Diehl JA, Cheng M, Roussel MF. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998, 15:3499-511.
27. Dong J, Peng J, Zhang H. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res. 2005, 65:1961-72.
28. Karim R, Tse G, Putti T. The significance of the Wnt pathway in the pathology of human cancers. Pathology. 2004, 36:120-8.
29. Massagué J. G1 cell-cycle control and cancer. Nature. 2004, 432:298-306.
30. Stewart ZA, Westfall MD, Pietenpol JA. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci 2003, 24:135-49.
31. Hiratsuka M, Inoue T, Toda T. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun. 2003, 309:558-66.
32. Diaz-Corrales FJ, Asanuma M, Miyazaki I. Rotenone induces disassembly of the Golgi apparatus in the rat dopaminergic neuroblastoma B65 cell line. Neurosci Lett. 2004, 354:59-63.
33. Inoue T, Hiratsuka M, Osaki M. SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene. 2007, 26:945-57.
34. Inoue T, Hiratsuka M, Osaki M. The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle. 2007, 6:1011-88.
35. Jackson JR, Patrick DR, Dar MM. Targeted anti-mitotic therapies: can we improve on tubulin agents. Nat Rev Cancer. 2007, 7:107-17.
36. Kappes A, Vaccaro A, Kunnimalaiyaan M. Lithium ions: a novel treatment for pheochromocytomas and paragangliomas. Surgery. 2007, 141:161-5.
37. Nahhas F, Dryden SC, Abrams J. Mutations in SIRT2 deacetylase which regulate enzymatic activity but not its interaction with HDAC6 and tubulin. Mol Cell Biochem. 2007, 303:221-330.
38. Obligado SH, Ibraghimov-Beskrovnaya O, Zuk A. CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases. Kidney Int. 2008, 73:684-90.
39. Rao AS, Kremenevskaja N, Resch J. Lithium stimulates proliferation in cultured thyrocytes by activating Wnt/beta-catenin signalling. Eur J Endocrinol. 2007, 153:929-38.
40. Shakoori A, Mai W, Miyashita K. Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer cells in rodents. Cancer Sci. 2007, 98:1388-93.
41. Smits VA, Essers MA, Loomans DS. Inhibition of cell proliferation by lithium is associated with interference in cdc2 activation. FEBS Lett. 1999, 457:23-7.
42. Tighe A, Ray-Sinha A, Staples OD. GSK-3 inhibitors induce chromosome instability. BMC Cell Biol 2007, 14:8.
43. Wakefield JG, Stephens DJ, Tavare JM. A role for glycogen synthase kinase-3 in mitotic spindle dynamics and chromosome alignment. J Cell Sci. 2003, 116:637-46.
44. Wang Y, Kreisberg JI, Ghosh PM. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets. 2007, 7:591-604.
45. Verdaguer E, Susana Gde A, Clemens A. Implication of the transcription factor E2F-1 in the modulation of neuronal apoptosis. Biomed Pharmacother. 2007, 61:390-9.
46. Pallàs M, Camins A. Molecular and biochemical features in Alzheimer's disease. Curr Pharm Des. 2006, 12:4389-408.
47. Camins A, Verdaguer E, Folch J. Involvement of calpain activation in neurodegenerative processes. CNS Drug Rev. 2006, 12:135-48.
48. Nunomura A, Moreira PI, Lee HG. Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. CNS Neurol Disord Drug Target. 2007, 6:411-23.
49. Zhu X, Lee HG, Perry G. Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta. 2007, 1772:494-502.
50. Webber KM, Casadesus G, Zhu X. The cell cycle and hormonal fluxes in Alzheimer disease: a novel therapeutic target. Curr Pharm Des. 2006, 12:691-7.
51. Dranovsky A, Vincent I, Gregori L. Cdc2 phosphorylation of nucleolin demarcates mitotic stages and Alzheimer's disease pathology. Neurobiol Aging. 2001, 22:517-28.
52. Aulia S, Tang BL. Cdh1-APC/C, cyclin B-Cdc2, and Alzheimer's disease pathology. Biochem Biophys Res Commun. 2006, 339:1-6.
53. Bonni A. The E2F-Cdc2 cell-cycle pathway specifically mediates activity deprivation-induced apoptosis of postmitotic neurons. J Neurosci. 2003, 23:1649-61.
54. Konishi Y, Lehtinen M, Donovan N. Cdc2 phosphorylation of BAD links the cell cycle to the cell death machinery. Mol Cell. 2002, 9:1005-16.